Despite many therapeutic advancements over the past decade, the continued rise in chronic inflammatory lung diseases incidence has driven the need to identify and develop new therapeutic strategies, with superior efficacy to treat these diseases. Statins are one class of drug that could potentially be repurposed as an alternative treatment for chronic lung diseases. They are currently used to treat hypercholesterolemia by inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, that catalyses the rate limiting step in the mevalonate biosynthesis pathway, a key intermediate in cholesterol metabolism. Recent research has identified statins to have other protective pleiotropic properties including anti-inflammatory, anti-oxidant, mucoinhibitory effects that may be beneficial for the treatment of chronic inflammatory lung diseases. However, clinical studies have yielded conflicting results. This review will summarise some of the current evidences for statins pleiotropic effects that could be applied for the treatment of chronic inflammatory lung diseases, their mechanisms of actions, and the potential to repurpose statins as an inhaled therapy, including a detailed discussion on their different physical-chemical properties and how these characteristics could ultimately affect treatment efficacies. The repurposing of statins from conventional anti-cholesterol oral therapy to inhaled antiinflammatory formulation is promising, as it provides direct delivery to the airways, reduced risk of side effects, increased bioavailability and tailored physical-chemical properties for enhanced efficacy.
Introduction
Statins are a class of drug widely used to lower cholesterol levels, consequently reducing the rates of stroke, myocardial infraction, vascular death, cerebrovascular events and mortality from coronary artery disease [1] . In the past decade, mounting evidence have shown that statins provide greater protection than predicted from just cholesterol lowering effects, possibly mediated by other pleiotropic actions. This includes antiinflammatory, anti-oxidant, immunomodulatory effects, improved endothelial cell function and anti-thrombotic actions [2, 3] . The exploitation of these pleiotropic statin-induced protective effects could be used therapeutically to manage chronic lung diseases with inflammatory and oxidative stress components such as asthma, chronic obstructive pulmonary disease (COPD) and pulmonary hypertension [4] [5] [6] [7] .
In recent years, despite the many therapeutic advancements, the frequency of chronic inflammatory lung diseases has continued to rise due to air pollution, tobacco smoke and occupational chemicals [8] . Currently, hundreds of millions of people suffer every day from chronic respiratory diseases (N235 million living with asthma and N64 million have COPD) and in fact, the World Health Organisation predicts that chronic lung disease will be the third most common cause of death by 2020 [9] . Chronic lung diseases are typically characterised by airway inflammation, thick hyperviscous mucus production and chronic infection. Taken together, these lead to the disruption of the mucociliary clearance mechanisms, bronchoconstriction and airflow limitation that subsequently manifest to debilitating symptoms such as cough, wheeze and breathlessness. Current treatments available to manage this condition are limited to bronchodilators, corticosteroid, nonsteroidal anti-inflammatory drugs and antibiotics, all of which are focussed on symptom elevation [10] . In addition, long-term exposure to these therapies could lead to reduced responsiveness (drug resistance) over time with a proportion of patients that do not respond well to these standard treatments [11, 12] . Therefore, statins may provide an important new alternative to treat chronic lung diseases. This review will outline current evidences for statins pleiotropic effects that could be used for the treatment of chronic inflammatory lung diseases. We will discuss in detail the mechanisms of actions by which statins exert their actions and the potential to repurpose statins as inhaled therapeutics, including a detailed discussion on their different physical-chemical properties that could ultimately affect treatment efficacies.
Mechanisms of actions
Originally, statins were used to lower cholesterol levels by inhibiting cholesterol synthesis. Statins block and completely inhibit the action of the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) Reductase enzyme, the rate-limiting enzyme responsible for the conversion of HMG to mevalonate, termed the mevalonate pathway [13] . By inhibiting HMG-CoA Reductase, statins stop the downstream synthesis of cholesterol ( Fig. 1 ), resulting in a transient decrease of cholesterol. Importantly, inhibition of HMG-CoA Reductase also prevents the synthesis of pyrophosphate intermediates, namely farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), from which prenyl groups (also known as prenoids) are derived [14] [15] [16] [17] . Prenoids are important posttranslational modifiers that covalently bind to specific proteins to facilitate protein association with the lipid membrane and also downstream protein-protein interactions [14, 15, 17] . Thus, while statins directly block the HMG-CoA Reductase activity to inhibit cholesterol synthesis, statins also indirectly inhibit preniods synthesis. As a result, statins act to modulate a number of intracellular signalling pathways that regulate inflammation, oxidative stress and immunity [18] [19] [20] . Despite decades of research, the exact molecular mechanism(s) that statins act to exert these pleiotropic effects remains unclear; this in itself, is a testament to the pleiotropicity of statins. The aim of this review section is to summarise and critically analyse the literature, focusing specifically on the molecular mechanisms and signalling pathways influenced by statin treatment, to better understand statin induced protection.
Currently, there are 8 statins available for in vivo and in vitro studies, atorvastatin, cerivavastatin (withdrawn from the market), lovastatin, simvastatin, fluvastatin, pravastatin, pitavastatin, and rosuvastatin. These can further be sub-grouped into one of two categories, lipophilic or hydrophilic (Table 1) . Generally, lipophilic statins are passively diffused across the membrane, while the hydrophilic statins require active transport (Fig. 2) . Several studies have reported significant differences in the efficacy of lipophilic and hydrophilic statins [21] [22] [23] [24] , resulting in differences in tissue permeability and metabolism, which will be discussed in detailed in Section 4.0 of this review. The most commonly studied statins are the lipophilic statins, specifically simvastatin, as it is thought to effectively enter the vascular cells by passive diffusion enabling the pleiotropic effects. In stark contrast, hydrophilic statins are primarily targeted to the liver and undergo degradation, that could potentially diminish their pleiotropicity [25] [26] [27] . Thus, when comparing the effects of statins or determining the molecular pathway of a specific statin-induced pathway, it is important to understand the properties of the particular subgroup [21] .
Protein prenylation, also referred to as lipidation, is the addition of a prenyl group to the carboxyl-terminus of a protein. Specifically, protein geranylgeranylation occurs to the GTPase superfamily of proteins: Ras, Rac, Rho, and Cdc42 [28] . While protein farnesylation is limited to the Rab proteins of the endocytic recycling pathway [14, 17] . A number of studies have identified that statin-induced protective effects are a direct result of geranylgeranylation inhibition and not farnesylation [29, 30] , highlighting a role for GTPase's in mediating the statin induced effects. The GTPase superfamily of proteins acts as a 'molecular switch' for a diverse range of signalling pathways that regulate cell migration, proliferation, and growth, and relies on the tethering of the GTPase to the cell Fig. 1 . Effects of inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase enzyme by statins on cholesterol biosynthesis pathway, which also generates isoprenoid intermediates, farnesylpyrophosphate (FTT) and geranylgeranylpyrophosphate (GGPP). Both these products are used in post-translational modification of proteins via prenylation. membrane [16] . As such, treating cells with statins decreases the prenylation of GTPase family members and therefore their association with the lipid membrane, consequently regulating GTPase activity [30] [31] [32] (Fig. 2) .
The statin mode of action: A combination of inhibiting cholesterol synthesis and prenylation
One of the key questions in the literature is to define and articulate the mechanism of action by which statins exert their pleiotropic effects. This has proved difficult due to the multitude of pathways that statins have been implicated in and affect. Thus, there is much debate in the literature as to whether the pleiotropic statin effects (anti-inflammatory, antioxidative and immunomodulation) are a direct result of the inhibition of cholesterol synthesis, the indirect result of the loss of prenyl group or a combination of the two. Most likely, it is a combination of the two, however many studies do not consider this when defining their mechanisms.
Statins regulate inflammation by decreasing intracellular cholesterol levels
As statins act to inhibit cholesterol synthesis, cells will respond by compensating for the loss of cholesterol. Cells have been shown to increase the expression and enzymatic activity of HMG-CoA Reductase [33] [34] [35] and are also suspected to increase the transcription of low-density lipoproteins (LDL)-receptors to maximise cholesterol uptake from serum [36] . However, later studies found that the increase in LDLreceptor mRNA did not correspond to an increase in LDL-receptor protein levels [23, 37] . Further investigation of this pathway found that statin treatment had increased the turnover of the LDL-receptor [37] , suggesting that statins may play a role in endosomal-mediated degradation of the LDL-receptor. Interestingly, the role prenylation of Rab endocytic vesicles played in LDL-receptor recycling has not been investigated in the study.
Reverse cholesterol transport is a mechanism by which cells actively efflux intracellular cholesterol via ATP-binding cassette (ABC) transporters to maintain intracellular lipid homeostasis [38] [39] [40] . In the lung, two ABC transporters have been identified: ABCA1 and ABCG1 [40] [41] [42] [43] . Statins act to regulate ABC transporter expression via two mechanisms. In the first, the statin induced decrease in oxysterol formation inhibits the extracellular-signal regulated kinase (ERK)1/2 -cyclooxygenase (Cox)-2 signalling axis, resulting in the decreased transcription of the ABCA1 and ABCG1 transporters [43] [44] [45] . Importantly, ERK1/2 is downstream of GTPase activity [46] (Fig. 3) . In the second pathway, the decreasing abundance of intracellular cholesterol triggers the transcription of sterol regulatory element binding protein (SREBP)-2 gene, containing the microRNA miR33, a known inhibitor of ABC Transporter transcription [47, 48] . Thus, the simultaneous expression of SREBP-2 and miR33 negatively regulate the transcription of the ABCA1 and ABCG1 transporters [23, 49, 50] . Statins have been shown to play a regulatory role in the expression of ABCA1 and ABCG1 transporters, albeit a controversial role, with numerous studies citing conflicting results. Some studies state that statins decrease the expression of ABC transporters [23, 51] , others have identified that statins increase ABC transporter expression and therefore increase cholesterol efflux [52, 53] , while another study states no change to ABC transporter expression [34] .
The statin-induced regulation of ABCA1 and ABCG1 transporter expression has been associated with the increase production and secretion Table 1 Chemical properties of statins affecting their pharmacokinetics profile and efficacies on various lipid factors after oral administration [137, 156] . ⁎ Efficacy was elicited in hypercholesterolemia patients taking a daily oral dose of 40 mg for atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin and rosuvastatin and 4 mg for pitavastation; # no significant effect reported; LCL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; GIT: gastrointestinal track, OATP: organic anion transporting polypeptide; OAT: organic anion transporter, NTPC: sodium-taurocholate co-transporting polypeptide; P-gp: P-glycoprotein. of inflammatory cytokines, highlighting a role for statins in mediating cellular inflammation [54] [55] [56] [57] . This occurs as a direct result of the statin-induced loss of ABC transporters as by blocking the efflux of cholesterol from cholesterol-loaded cells (mimicking hypercholesterolemia), creating a build-up of intracellular cholesterol. This increase in intracellular fatty acid is then trafficked to the endoplasmic reticulum creating a 'fatty acid overload' at the reticulum membrane [58] , suggesting a possible role for Rab proteins. Importantly, this 'overload' activates a number of downstream signalling pathways, including mitogen activated protein kinase (MAPK) p38, ERK1/2, and the nuclear factor (NF)-κB, resulting in the increased production and secretion of both pro-and anti-inflammatory cytokines (tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, IL-12p20) [20, 55, 56, 58, 59] (Fig. 3 ).
Statins increase anti-inflammatory cytokines and anti-oxidative mediators via regulating GTPase activity
An important aspect of statin induced anti-inflammatory effectsthat is not often studied in parallel with the mechanism outlined above -is the role of prenylated GTPase proteins. Specifically, the GTPase superfamily of Rac, Rho, Ras, and Cdc42 that are upstream of MAPK p-38, ERK1/2, c-Jun N-terminal kinase (JNK) and NF-κB activation [24, [60] [61] [62] . As statins reduce the synthesis and therefore amount of prenyl groups available for prenylation, statins inhibit the association of GTPases with the membrane resulting in the functional inactivation of these molecules [30] [31] [32] .
The GTPase superfamily regulates multiple pathways including cellular architecture, proliferation and migration. Important to this review is the role GTPases play in regulating downstream signal transduction of inflammatory mediators. In response to extracellular inflammatory signals, GTPases are recruited and anchored to the membrane [31] . GTPase family members Rac and RhoA, initiate downstream signalling that involves numerous intermediates (Fig. 3) , most notably via the MAPK/NF-κB signalling axis to initiate synthesis of pro-inflammatory cytokines TNF-α, IL-6, IL-8 and pro-inflammatory intermediates intracellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 to name a few [29, 32, 53, 61, [63] [64] [65] [66] . Importantly, cells treated with a variety of hydrophilic and lipophilic statins treatment show decreased Rac/RhoA-activity and therefore decreased downstream cytokine synthesis and secretion [32, 61, 65] . Additional studies have then further confirmed the role of prenylated GTPases play in regulating cytokine synthesis as chemical inhibition of prenylation reported similar results [18, 29, 30, 62, 67] .
Of equal importance is the role statins play in modulating the oxidative stress pathway. Statins are known to reduce cellular oxidative stress via two mechanisms: 1. By inhibiting Rac mediated activation of the nicotinamide adenine dinucleotide phosphate (NAPDH)-oxidase pathway [68] . Activation of NAPDH must occur at the membrane, indicating Rac must be prenylated to initiate the signalling cascade that results in the generation of reactive oxygen species (ROS) and the subsequent activation of NF-κB-mediated transcription [29, 69] . To initiate the signalling pathway, Rac must interact with NAPDH at the membrane and thus Rac must be prenylated [32] . 2. By inhibiting the prenylation of the Ras family member, Rap-1 [70] . Unprenylated Rap-1 has been shown to activate the mitogen-activated protein kinase kinase (MEK)-5/extracellular signal-regulated kinase (ERK)-5 signalling axis [29, 70] (Fig. 3) . Interestingly, MEK5 is a member of the MAPK family, yet the structure and signalling events that occur downstream of the interaction MEK5/ ERK5 are distinct to that of MAPK-mediated signalling [71, 72] . MEK5 is the only known kinase to phosphorylate and activate ERK5 [73, 74] . As such, statins have been shown to increase ERK5 kinase activity [22, 32, 75] leading to the downstream activation of transcription factors, monocyte enhancing factor (MEF)2 and krupple-like factor (KLF)2 [76] . MEF2 and KLF2 both inhibit endothelial inflammation via independent pathways: MEF2 inhibits the expression of a known proinflammatory protein, cytokine-mediated adhesion molecule, [77] , while KLF2 induces transcription of endothelial Nitric Oxide Synthase (eNOS), a potent anti-inflammatory mediator [24, [77] [78] [79] . Interestingly, overexpression of KLF2 was shown to attenuate expression of the proinflammatory mediator VCAM-1 [24] by muting the cytokinemediated activation of Rac and subsequent downstream signalling [76, 80] .
Potential role of statins in the treatment of respiratory diseases
In light of the pleiotropic actions of statins, there is the potential for statins to be used to treat a number of inflammatory-mediated respiratory diseases.
Cellular inflammatory and oxidative stress processes in the airways
In chronic lung diseases, the cascade of uncontrolled inflammatory processes is the main driver of disease pathogenesis and progression. Exposure of the respiratory system to a variety of stimuli such as infection (bacteria or virus), allergens (pollens, house dust mites) and airborne pollutants (dust, combustibles, cigarette smoke) play an important role in causing and perpetuating inflammation in the airways [81] . During the inflammatory processes, epithelial cells and alveolar macrophages are activated as the first line of defence and results in the subsequent sequestration of other inflammatory cells from the systemic circulation (i.e. neutrophils, eosinophils, monocytes and lymphocytes) in to the respiratory bronchioles and airway lumen to release pro-and antiinflammatory cytokines (IL-1, IL-4, IL-5, IL-6, IL-8, IL-13, IL-1β, TNFα, IFN-γ). The release of these cytokines amplifies the production of cytokines and activation of additional inflammatory cells via the MAPK/NF-κB signalling pathway exaggerating the inflammatory responses further in chronic respiratory diseases [82] .
In addition, inhalation of airborne pollutants also creates an exogenous, as well as endogenous (through nitric oxide, NO production) oxidant load, generating reactive oxygen species (ROS) and nitrogen oxygen species (such as superoxide anion and hydroxyl radical) that are capable of initiating oxidative stress in the airways. Overproduction of these reactive species contributes to tissue damage and lung injury that are associated with DNA, RNA and protein damage as well as lipid oxidation [81] . Specifically, these reactive species also inactivate many of the anti-protease mediator that are important in maintaining respiratory homeostasis, such as α 1 -antitrypsin, serine antiproteases and α 1 -antichymotrypsin and consequently resulting in an acquired anti-protease deficiency, important in maintaining respiratory homeostasis. Activated macrophages also produces a number of matrix metalloproteases (notably MMP1, MMP2, MMP9, MMP12 and MMP15) that have the ability to degrade both elastin and collagen fibres and therefore destroy the structural integrity of the lung. The altered protease/antiprotease balance, skewed in favour of proteases activity, leads to the development of emphysema, poor elastic recoil of tissues, excessive remodelling (airway fibrosis), further damaging the lung parenchymal and the increased susceptibility to respiratory infections [4, 83, 84] .
Another hallmark characteristic of chronic lung diseases is the excessive mucus production. This contributes to the cycle of airway obstruction, inflammation and infection if not cleared from the lung. Hypermucus secretion is due to goblet cell hyperplasia and upregulation of the various inflammatory cytokines (i.e. neutrophil elastase, TNFα, IL-1β, EGF, IL-13) that are concurrently associated with the increased transcription and translation of two mucin genes: MUC5AC and MUC2 proteins [85] . These mucin proteins in turn are responsible for increased mucin production, which is the major component of mucus and is highly regulated in the airway epithelia via the RhoA/ p35 pathway [86] .
Of direct relevance to the discussed pleiotropic mechanisms, statins have been shown in vitro and in vivo to exert its beneficial protective effects for the treatment of chronic lung disease through 2 main actions in the airways: [175] Retrospective study Fluvastatine, simvastatin, pravastatin, atorvastatin, and rosuvastatin
3371
Not reported
• Statin use associated with improved short-(30 days followup) and long-(10 years follow-up) term survival in patients with peripheral arterial diseases with and without COPD • Transient and significant reduction in right ventricular hypertrophy and N-terminal pro-B-type natriuretic peptide but not sustained over 12 months Zeng et al. [189] RCT Atorvastatin (10 mg/day) 220 24 weeks
• No beneficial effect was observed • No significant difference observed between groups in 6-min walk distance, pulmonary vascular resistance, cardiac output and proportion of patients who improved, remained stable or showed deterioration. Kawut et al. [190] RCT Simvastatin (40 mg/day) 65 6 months
• No significant different in 6-min walk distance or biomarkers of endothelial dysfunction or injury Barreto et al. [191] RCT Rosuvastatin (10 mg/day) 60 6 months
• Lower P-selectin levels, which is crucial in inflammation and thrombosis in PAH • No significant changes in other markers (tissue--plasminogen activator and von Willebrand factor antigen) Liu et al. [192] RCT Atorvastatin (20 mg/day) 68 6 months (continued on next page)
(1) Reducing airway inflammation and oxidation through their roles in regulating NOS, decrease inflammatory cytokine production and reduction of inflammatory cells influx into the airways [87] [88] [89] [90] [91] [92] [93] , as well as; (2) Attenuating airway remodelling by regulating cellular architecture and function and reducing airway epithelial changes. Studies have shown that statin treatment could reduce contractile and proliferative properties of airway smooth muscle cells during airway hyperresponsiveness [94, 95] , regulate MMP expressions [96, 97] , and decrease MUC gene expression leading to decreased mucin production and suppression of goblet cell hyperplasia [98] [99] [100] [101] [102] [103] [104] .
Hence, given the diverse pathways affected by statins through their inhibition of cholesterol synthesis and intracellular prenylation and subsequent GTP-binding proteins that underlie key pathway components of chronic inflammatory lung diseases, it is not surprising that repurposing of statins provides an exciting new opportunity for the treatment of these diseases.
Clinical trials on statins
The overwhelming positive results derived from preclinical studies involving statins have fuelled the interest of clinical studies over the past decade. Key clinical trials on the use of oral statins to treat chronic respiratory diseases such as asthma, COPD, acute lung injury and pulmonary hypertension that have been performed over the past 10 years have been summarised in Table 2 . Although numerous in vitro and in vivo animal studies have demonstrated beneficial effects of statins to treat chronic respiratory diseases, the overall results and conclusions from clinical trials were not consistent. Several studies demonstrated improved outcomes from statin therapies, and other studies reported otherwise. These conflicting results may be attributed to several issues, but mainly is due the oral delivery of statins. Oral delivery of statins results in low systemic bioavailability and subsequent varying sub-therapeutic levels of statins in the airways for its pharmacological efficacies. The low levels of statins in the lungs are unfavourable since their main pharmacological targets are the airway epithelium, alveolar macrophages, fibroblasts, endothelial cells and inflammatory cells, which are responsible for the inflammatory cascade in chronic airway diseases. Additional issues that need to be considered include the different types of statin which may exert various antiinflammatory efficacies, the required optimal dose to be delivered to the airways for effective therapeutic outcomes, the duration of statin treatment required before therapeutic effects can be observed, whether statins are better as an alternative sole therapy or as an adjunct/combination with other therapies, and finally if statins are only effective in a specific patient population phenotype [105] .
Inhalation of statins
One of the major problems in using statins to treat chronic respiratory diseases, is the need for high doses of drugs to be administered to reach therapeutic concentrations in the airways for its clinical efficacies. This has contributed to conflicting results and observations in clinical trials investigating the protective roles of oral statins in patients with various respiratory diseases ( Table 2 ). To complicate matters further, statins have low bioavailability following oral administration owing to the different lipophilic properties of the molecules, high first-pass metabolism in the liver and intestines, as well as rapid systemic clearance with short half-lives. The resultant adverse effects from high oral doses of statins include hepatotoxicity, nephrotoxicity, myalgia, rhabdomyolysis and multiple drug interactions with other concomitant therapies and food intake due to its extensive metabolism by hepatic microsomal cytochrome P450 isozymes [106, 107] . Therefore, delivery of statins via the inhalation route could provide a unique opportunity and an important alternative to circumvent these problems. Ideally, inhaled statins will deliver high drug concentrations directly to the lungs using relatively lower doses with minimal drug degradation and systemic absorption compared to oral administration. This will provide efficient and effective therapeutic effects while simultaneously reducing the risk of unwanted side effects.
There are a number of ways to classify statins including: (1) how they are synthesised (natural or synthetic), (2) physico-chemical properties according to their aqueous solubility (hydrophilic or lipophilic), (3) chemical structure-linked to pharmacological activity (active open ring acid or inactive lactone forms), and (4) statin generations based on their increasing safety profiles, potency and efficacy in lowering plasma low-density lipoprotein cholesterol (LDL-C) concentrations [107, 108] . Consequently, statins may also exert differential antiinflammatory efficacies for treatment of lung diseases based on their physico-chemical properties that will in turn affect absorption, intracellular uptake mechanisms and activation of statins in vivo. Table 1 summarises the different classifications of statins based on their physicochemical properties, pharmacokinetic profiles and efficacies on various lipid factors. There have been several studies that have shown promising anti-inflammatory properties for statins to be formulated for pulmonary administration for chronic respiratory diseases rather than its conventional oral anti-cholesterol activity. These studies will be discussed in the following review sections in relation to statins physicochemical characteristics and pharmacokinetics parameters.
Simvastatin
Simvastatin is one of the most effective HMG-CoA reductase inhibitor for lowering cholesterol and associated cardiovascular risk. Combined with its affordability and availability of simvastatin generics drugs on the market, simvastatin is the most prescribed and wellstudied statin molecule in terms of its anti-inflammatory potential and pleiotropic actions in literature. However, there are several issues to consider when formulating simvastatin as an inhaled formulation, which includes its low water solubility and chemical instability when in solution [103] . The lactone ring of the simvastatin structure renders this lipophilic prodrug susceptible to hydrolysis and oxidative reactions, forming four metabolites: simvastatin hydroxy acid (SVA), 6′-exomethylene SV, 6′-ß hydroxy-simvastatin, and 3′-5′-dihydrodiol simvastatin [109] . Yet, SVA is the active metabolite of simvastatin that is responsible for its therapeutic effects and is found to be 400 times more hydrophilic than simvastatin (log P of 4.68 at pH 7) [110] . Although the lipophilic simvastatin can passively diffuse across the cell membranes without the need for specific transporter uptake, [194] Retrospective study Atorvastatin, simvastatin 112 Not reported
• Study performed in patients with secondary PAH to COPD • In patients with COPD, significant reduction in pulmonary arterial pressure and pulmonary artery pressure was observed • No difference in pulmonary vascular resistance hydrophilic SVA is poorly absorbed by the body, including respiratory cells, possibly limiting its pharmacological action [100, 111] . Therefore, simvastatin must be delivered in its stable pro-drug form to the airways to achieve maximum therapeutic efficacy to treat chronic airway diseases. Once in the lungs, simvastatin is activated into SVA by cytochrome P450 (CYP) isozymes and microsomial carboxylesterases (CES), specifically CYP3A4/5 and CES1A1 -the same enzymes responsible for simvastatin metabolism in the liver. Previous studies by Munger et al. [112] and Anttila et al. [113] have found that these CES and CYP enzymes are expressed on the membrane surface of alveolar cells, bronchiolar cells, lung epithelial cells and alveolar macrophages. Hence, it is assumed that after deposition and dissolution of simvastatin into the airway lining fluid, the lipophilic drug molecule will then diffuse across the lipid bilayer membrane of the various respiratory cells and be metabolised into its active SVA metabolite by the CES and CYP enzymes to initiate its pharmacological effects.
To date, there are only a handful of studies that have investigated the potential of delivering simvastatin directly to the airways. The majority of these studies are performed using intraperitoneal administration of simvastatin in different animal models of various respiratory diseases including asthma, emphysema and ventilator induced injury [93, 114, 115] . The earliest study to investigate inhaled simvastatin was conducted by Tschernig et al. [116] that compared the effects of a single dose of intraperitoneal and intratracheal administration of simvastatin prior to ovalbumin challenge in allergic airway inflammation in a rat model of asthma. In this study, different dosages were used for the two different routes of simvastatin administration with a higher dose of simvastatin administered intraperitoneally (10 mg, 1 mg and 0.1 mg) compared to intratracheal administration (1 mg and 0.1 mg). It was found that both administration routes partially reduced the numbers of neutrophils, eosinophils and lymphocytes with increasing doses of simvastatin, with the most notable effect observed on CD4 T cell numbers, an important mediator of asthma pathophysiology. Importantly, the authors noted that intratracheal administration of 0.1 mg simvastatin significantly reduced the number of eosinophils to levels comparable to the intraperitoneal administration of 10 mg simvastatin dose.
Similar findings were also observed in a study by Xu et al. [117] that investigated the anti-inflammatory properties of inhaled simvastatin compared to intragastric injections of dexamethasone corticosteroid. The study also compared the pharmacokinetic profiles of simvastatin delivered locally to the airways by inhalation, intratracheal injection or systemically by intraperitoneal injection and gavage in a mice model of asthma. The pharmacokinetic study was performed using a single dose of simvastatin (5 mg/mL), while the anti-inflammatory efficacy study was evaluated with simvastatin treatment once a day for 7 days at 1, 5, or 20 mg/mL (dissolved in 20% ethanol and 80% saline) dose delivered by a jet nebuliser for 10 min. Local administration of simvastatin showed significant reductions in airway inflammation, remodelling and hyper-responsiveness in a dose dependent manner similar to corticosteroids dexamethasone. Concurrently, the study reported that higher drug concentrations were detected in local lung tissues with lower plasma drug concentration compared to the drug administered systemically (100 mg/kg). The pharmacokinetic profile of a single dose of nebulised simvastatin (with 10% ethanol) in the lungs and systemic circulation was also confirmed in a recent study that used healthy rhesus macaque non-human primates to determine the metabolism and distribution of simvastatin [118] . Simvastatin and SVA were able to achieve maximum concentration inside the airway epithelial cells at time 0 and 1 h post exposure and were both cleared within 6 h. Additionally, simvastatin appears to enter the systemic circulation immediately after drug administration but was rapidly cleared by 3 h, with no evidence of harm or injury to the animals. This evidence further support the benefits of using inhalation strategies to reduce the oral doses required to obtain enhanced therapeutic efficacy in the airways and reduce the incidence of side effects.
The efficacy of localised delivery of simvastatin by inhalation (0.06, 0.6 or 6 μg/kg) over a 2-week period has also been demonstrated in additional studies [119] [120] [121] that used house dust mite allergen challenged mice models of airway inflammation and hyper-reactivity. Furthermore, these studies also demonstrated that intranasal administration of simvastatin was able to suppress allergic airway inflammation and hyperactivity. The mice in these studies displayed reduced numbers of inflammatory cells such as eosinophils and neutrophils in the bronchoalveolar lavage and lung histology samples in a simvastatin-dose dependent manner. However, considering the lipophilic nature and instability of the simvastatin molecule in vitro and in vivo, a critical issue with these studies is the lack of information on the simvastatin formulation that was used to deliver the drug to the lung. This also includes drug stability, aerosol performance, solubility in the various vehicle used, physical-chemical properties and whether a dry powder or solution based formulations were utilised, all of which could ultimately result in differential pharmacokinetic, toxicity and efficacy profiles when translated to human studies.
More recently, several inhalation formulations of simvastatin that have addressed the issues of stability, dosages and aerosol performance have been developed including a low dose pressurised metered dose inhaler (pMDI, 150 μg/actuation) [101, 122] , dry powder for inhalation (DPI) [102] and nebulised nanoparticles [103] , as potential treatment of mucus overproduction and inflammation for respiratory diseases. These formulations have been shown to possess favourable physical and chemical properties with a demonstrated good chemical stability of simvastatin up to 3-9 months in various storage conditions, and suitable aerosol performance to reach the deep lungs. More importantly, these inhaled simvastatin formulations demonstrated antiinflammatory activities, muco-inhibitory efficacy, anti-oxidant properties and superior safety profiles over a wide range of drug concentrations. Therapeutic efficacies of the formulations were investigated using a physiologically relevant in vitro model set-up shown to be predictive of ex vivo and in vivo activity, that combined an air interface Calu-3 bronchial epithelial cell model with a twin stage impinger to simulate realistic airway drug deposition [123] [124] [125] [126] . The study showed significant inhibition of mucus production, inflammatory cytokine release (IL-6 and IL-8) and oxidative stress (ROS) in cells treated with simvastatin formulations when compared to untreated cells stimulated with lipopolysaccharide to mimic the inflammatory process in the airways. The nebulised simvastatin nanoparticles encapsulated with a poly(lactic-co-glycolic) acid (PLGA) and Pluronic F-127 formulation [103] , had an added benefit of controlled release properties and superior cytotoxicity profile, compared to the other simvastatin formulations. In turn, these properties resulted in sustained anti-inflammatory actions and potentially better patient compliance for up to 48 h. In these studies, the direct administration of the pro-drug simvastatin into the lung as pMDI, DPI or nebulised nanoparticle suspension was converted into the active SVA metabolite, with almost 40% of the simvastatin delivered being converted to SVA intracellularly. This reaffirms the ability of inhaled simvastatin to diffuse and penetrate into the airway epithelium and be subsequently converted to SVA metabolite. Hence, the repurposing of simvastatin in these inhaled formulations could potentially be used to treat chronic pulmonary diseases locally where hyper-mucus production and uncontrolled inflammation are key features of the disease. However, further in vivo and clinical studies are required to translate these treatments to the clinical setting as well as to determine a safe and effective therapeutic dose.
Hydrophilic statins: Pravastatin and rosuvastatin
Another potential statin therapy that has shown promising antiinflammatory properties when delivered by inhalation is pravastatin. Unlike simvastatin, which is, the most lipophilic statin molecule used clinically, pravastatin is the most hydrophilic, with partition coefficient of −0.84 at pH 7.4. The pharmacokinetics of inhaled pravastatin, as well as efficacy to reduce airway inflammation and mitigate structure damage, was investigated in a recent study in a murine allergic model [127] . The authors found that intratracheal instillation of watersoluble pravastatin was able to achieve relatively high concentrations of drug in the bronchoalveolar lavage fluid and lung tissue with minimal systemic absorption and no damage to the airway epithelium. However, no statistically significant anti-inflammatory effects on inflammatory cell influx in the lungs were reported nor was pravastatin shown to attenuate airway hyper-reactivity or preserve lung compliance. Importantly, inhaled pravastatin was effective in reducing goblet cell hyperplasia and metaplasia as well as secretion of selected cytokines (TNF-α and keratinocyte chemoattractant, KC), but not other cytokines/chemokines including IL-13, IL-4, IL-5, IL-1α, IL-1β, IL-17, interferon gamma-induced protein 10 (IP-10), IFNγ, or regulated on activation, normal T-cell expressed and secreted (RANTES). The lack of anti-inflammatory efficacy with pravastatin is most likely due to it hydrophilic properties, preventing efficient entry via passive diffusion into respiratory cells such as epithelium and immune cells.
The active form of all statins is the 'open ring' hydroxy acid (such as simvastatin and lovastatin hydroxy acid) that binds to the active site of the HMG-CoA reductase enzyme to inhibit its enzymatic function. Pravastatin is administered as the active hydroxy form and is not readily absorbed by cells when compared to the more lipophilic inactive statins, simvastatin and lovastatin. Consistent with this, the findings of Marin et al. [100] , demonstrated that the transport of the open ring SVA into and across Calu-3 bronchial epithelial cells was significantly lower compared to its inactive 'close lactone ring' simvastatin counterpart. Hence, intracellular uptake of pravastatin requires membrane transporters such as organic anion transporting polypeptide (OATP), primarily OATP1B1 to facilitate transport into the effector cells [128, 129] . Importantly, the OATP1B1 transporter is not known to be expressed in the human lung tissues [130, 131] . Although pravastatin can be easily delivered directly to the airways in solution form, the lack of mechanisms to enter the cells could have prevented the drug from reaching sufficient intracellular concentrations to exert its therapeutic anti-inflammatory effects. Therefore, statin polarity properties (i.e. hydrophilicity, lipophilicity) not only determine experimental designs with respect to drug delivery and solubility, but are also equally important considerations for cell penetration that in turn affect bioavailability, potency and efficacy of the various statin molecules as anti-inflammatory agent in the airways.
Another hydrophilic statin molecule that has the potential for inhalation delivery is rosuvastin, which is a newer generation of statin also termed superstatin, delivered in its active open ring form [107] . Rosuvastatin is a fully synthetic HMG-CoA reductase inhibitor, whereas the other statins are natural, mevinic derived or synthetic, heptenoic acid derived. While the characteristics of all statin pharmacophores remain similar, the addition of a stable polar methane-sulphonamide group and fluorinated phenyl group to the rosuvastain molecule provide low lipophilicity and enhanced binding affinity with the HMG-CoA reductase enzyme. The strong ionic interactions between rosuvastatin and HMG-CoA reductase enzyme (four times greater compared to the native HMG-CoA reductase) [132] are responsible for its superior efficacy, potency and slow HMG-CoA reductase enzyme recovery following statin clearance compared to the older generations of statin molecules [133] . However, since rosuvastatin is a hydrophilic statin, it relies on the OATP1B1 transporters as the key mechanism for active transport into the various cells [134] , which may be absent in the pulmonary tissues as previously discussed. Nevertheless, Patil-Hadhe, A. et al. [135] have successfully formulated rosuvasatin loaded nanostructure lipid carrier in the form of solid lipid nanoparticles using a mixture of lauric acid and capryol 90 (7:3) . This mechanism of rosuvasatin delivery has the potential as an anti-inflammatory therapeutic for pulmonary application to attain high and sustained drug concentrations in the lung tissue. The dry powder formulation was evaluated for its physical-chemical characteristics, in vitro aerosol performance and in vivo pharmacokinetics in a murine model. The study found that the formulation produced particles of b200 nm in size, high drug encapsulation efficiency, sustained drug release over an extended 24-hour period as compared to the 3 h for the free drug with aerosol performance suitable for the deep lung when lyophilized with mannitol as a cryoprotectant-carrier. In addition, the in vivo pharmacokinetics of the rosuvasatin nanostructure lipid carrier formulation demonstrated higher Cmax, improved elimination half-life, and an improved area under the plasma concentration-time curve (AUC) when compared to pure drug solution, indicating significant bioavailability of rosuvastatin in the lungs. It was postulated that the lipid nature and smaller size of the nanoparticles enabled the particles to bypass macrophage clearance leading to lower lung clearance and help facilitate entry of rosuvastatin molecule into pulmonary airway epithelial cells. However, the antiinflammatory and antioxidant effects of the rosuvastatin formulations were yet to be explored, which is critical for it to be an effective therapy.
Pitavistatin
Pitavastatin is another third generation superstatin and a very potent inhibitor of the HMG-CoA reductase enzyme. Its chemical structure with a quinolone ring at the core and a flouro-phenyl group is similar to the other statins, especially fluvastatin and rosuvastatin. The presence of a cyclopropyl side chain is unique to pitavastatin, making it moderately lipophilic. Consequently, the addition of this side chain confers several distinct pharmacokinetic and pharmacodynamics properties to the drug molecule when compared to other statins [136] . This structure makes pitavastatin a stronger inhibitor of HMG-CoA reductase activity than other statins, including rosuvastatin. As such, pitavastatin requires a lower dose to inhibit cholesterol synthesis and elevate high-density and apolipoprotein A1.Pitvastatin undergoes minimal metabolism resulting in higher bioavailability and extended duration of action, and has a unique metabolic profile that reduces the potential for drugdrug and drug-food interactions [136] . The metabolic properties of pitavastatin are similar to that of the other hydrophilic statins, having a clinically insignificant metabolism occurring via the CYP2C9 pathway [137, 138] .
In terms of its pleiotropic effects, pitavastatin behaves similarly to other statins as a modulator of a variety of vascular, inflammatory markers, endothelial nitric oxide synthases and endothelial cells. In vitro studies have found that pitavastatin displayed the most potent effects on proliferation of pulmonary artery smooth muscles and endothelial cells when compared to other marketed statins [139, 140] . Further to this, Chen et al. [141] investigated the use of inhaled pitavastatin formulated as PLGA polymeric nanoparticles to improve the efficacy and reduce the side effects when treating pulmonary artery hypertension. Using a rat model of monocrotaline-induced pulmonary artery hypertension, the delivery of pitavastatin polymeric nanoparticles directly to the lung was found to me more effective than intratracheal delivery of pitavastatin alone or systemic delivery of pitavastatin in reducing the development of pulmonary artery hypertension. Nanoparticle formulation of pitavastatin induced the regression of established pulmonary artery hypertension and improved the survival rates of the rats. Interestingly, no therapeutic effect was observed following the inhalation of pitavastatin suspension alone, although the concentrations of pitavasatin in the lung and systemic circulation were similar to animals treated with the same dose (100 μg) of intratracheal pitavastatin suspension alone and the nanoparticle formulation. In addition, the study found that oral daily doses of pitavasatatin over 21 days at 1, 3, and 10 mg/kg per day (cumulative doses = 84, 252 and 840 mg per animal, respectively) showed similar therapeutic benefits to a single dose of 0.1 mg inhaled pitavastatin nanoparticle formulation, a dose equivalent to~850 times lower than the cumulative systemic doses. These observations suggest an added benefit of using inhaled nanotechnology to mediate intracellular delivery of pitavastatin directly to the lung to induce greater therapeutic effects. The very limited solubility of the pitavastatin in aqueous solutions (0.426 mg/L) [142, 143] may potentially limit drug exposure and subsequent uptake by target cells and could have been further complicated by the requirements for cellular uptake mechanisms, which are mediated by various transporters including OATP1B1, OATP1B3, organic anion transporter 3 (OAT3) and sodium(Na)-taurocholate cotransporting polypeptide (NTCP) [144] [145] [146] . Interestingly, encapsulating pitvastatin within the nanoparticle negates this challenge. The findings in this study emphasise the importance of targeted delivery, as well as formulation technologies, to circumvent certain physical-chemical properties of the drug molecule to improve drug solubility into the limited airway surface liquid. Nanotechnologies could also bypass the requirements for facilitated transporter through endocytic mechanisms [147] for intracellular drug uptake leading to improved drug efficacies.
Atorvastatin
Atorvastatin is another second generation statin that is administered as the active hydroxy acid and not as the lactone prodrug [148] . In vivo, atorvastatin is converted to its lactone form and appears to have the same AUC as its active hydroxy acid form after oral administration. Interestingly, the acid and lactone forms of atorvastatin have different partition coefficient octanol/water (log D values) at pH 7.4 of 1.53 and 4.2 respectively, which consequently have an impact on the pharmacokinetics in terms of partition into biological membranes and diffusion across membranes [149] [150] [151] . Atorvastatin is subjected to extensive metabolism by CYP3A4 and is converted into two active forms of the metabolite, 2-hydroxy-atorvastatin acid and 4-hydroxy-atorvastatin acid, both of which are in equilibrium with their inactive lactone forms [152] . Hence, intracellular uptake mechanisms of atorvastatin are mediated by both passive and carrier mediated processes depending on its form. The lactone form is transported via passive diffusion as it is more lipophilic in nature, while the atorvastatin acids are substrates for cellular membrane transporters of P-glycoprotein (P-gp) and OATP C [148] .
As with most statins, there is increasing evidence to show that atorvastatin also exerts pleiotropic properties, independent of the lipidmodifying properties. By inhibiting the synthesis of isoprenoid compounds, atorvastatin modifies inflammatory responses, endothelial cell function and smooth muscle cell proliferation [153, 154] . A recent study by Pinho-Ribeiro, M. et al. [155] investigated the efficacy of inhaled atorvastatin versus inhaled simvastatin on inflammation, oxidative stress and lung repair in a murine model of chronic obstructive pulmonary diseases with emphysema caused by long term exposure to cigarette smoke. This was the first study to our knowledge to compare the pleiotropic efficacies of different inhalation statins. In the study, mice were exposed to smoke from 12 cigarettes per day for 60 days to induce pulmonary emphysema. Mice were then treated with either atorvastatin (1 mg/mL), simvastatin (1 mg/mL), or a vehicle control that were administered in aerosol form for 15 min once per day for a further 60 days. Both atorvastatin and simvastatin improved the pulmonary morphologies and function due to the restoration of extracellular matrix, decreased influx of inflammatory cells and the subsequently reduced release of inflammatory mediators and oxidative stress damage. The most notable difference between the two statins was that atorvastatin showed better anti-inflammatory properties when compared to simvastatin. Mice treated with atorvastatin demonstrated a significant reduction in the number of inflammatory cells (i.e. macrophages and neutrophil) in the bronchoalveolar lavage fluids and associated cytokine levels. On the other hand, the ability of simvastatin to improve lung repair and airway function is most likely related to its anti-oxidative stress. In the study, inhaled simvastatin demonstrated superior anti-oxidant effects compared to atorvastatin, and seems to be the pharmacological major action against inflammation with lower levels of lipid peroxidation and reduced redox marker formation (such as reactive oxygen species, superoxide dismutase, catalase activity).
The mechanisms of how the statins elucidate its differing actions were not discussed. While the findings provided some insights into the differing efficacies of the different statins that could potentially guide therapeutic approaches for treatment of chronic lung diseases, a major limitation with the study is the lack of information regarding the formulations of the inhaled statins. Details regarding the stability/form of the statins, vehicle used to deliver the statin solution and physical-chemical properties were not reported, which have been shown in previous studies (discussed in this review) to have an effect on intracellular drug uptake, pharmacokinetics and ultimately efficacy in the airways.
Conclusions
Despite therapeutic advancements, incidence of chronic inflammatory lung disease continues to increase every year due to air pollution, tobacco smoke and occupational hazards. These debilitating diseases do not only affect a patient's quality of life but also creates huge burden on the health care system, as well as a country's social-economic sector. Furthermore, current treatment options are limited and may not be effective for all patient populations. Hence, new treatment options with superior efficacies to treat these diseases are urgently required as potential substitution, alternative or adjunct therapy to currently available therapies. However, the discovery of new molecules and development of formulation that are safe and effective has become increasingly challenging in recent years. To address this issue, the repurposing of conventional older drug molecules for different therapeutic applications either by changing its treatment indication, route of administration or formulation properties, are a highly feasible solution. A comprehensive understanding of the pharmacological mechanisms, drugs physicalchemical characteristics, safety and efficacies are therefore fundamental to the repurposing of drugs prior to market approval. There are also several other potential advantages of conventional drug repurposing compared to the discovery of new drug molecule, which include: 1) a wellestablished commercial manufacturing scale and quality control of the active pharmaceutical ingredient, 2) lower manufacturing costs, 3) lower systemic drug concentrations following the inhalation of statins compared to approved oral statin doses together with the known systemic pharmacokinetics, metabolism, distribution and safety should significantly reduce the product development risks, cost and timelines associated with investigations of systemic toxicity and drugdrug interactions with new chemical entities, and 4) well documented active pharmaceutical ingredient properties. Nevertheless, the repurposing of drugs still requires the development of a suitable formulation and delivery system with long term stability, manufacturing capability, inhalation safety and carcinogenecity profiles in animals, as well as proven safety and efficacy studies in humans.
This review has highlighted the potential of statins as an effective therapy for the treatment of chronic lung diseases that have conventionally been used for the treatment of hypercholesterolemia. Statins have been shown to have multiple pleiotropic effects other than its lipid lowering activity by modulating multiple signalling pathways that govern inflammatory, muco-inhibitory, oxidant stress and proliferation. While it is clear that statins have a protective role that could be exploited for the treatment of chronic lung diseases, the use of oral statins in clinical trials to treat these diseases have been nonconclusive. This controversy is most likely due to the statin delivery routes used in the trial, i.e. oral versus inhalation, which continues to be the main limiting factor in directly assessing the beneficial effects of statin as potential anti-inflammatory agents. No clinical studies have been published to date on the use of inhaled statins. Furthermore, studies on reformulating statins as an inhaled therapy are still in their infancy and further investigations are required to better understand the efficacy, toxicity and mechanism of action of these statin molecules in the airways.
Numerous in vitro and in vivo studies have demonstrated the protective effects of statins for the treatment of chronic inflammatory lung conditions. Clearly, the treatment efficacies of statins will be greatly enhanced compared to oral delivery when delivered directly to the airways by inhalation, reducing the incidence of side effects and potential for drug-drug interactions. Therefore, the repurposing of statins from conventional anti-cholesterol oral therapy to inhaled anti-inflammatory formulation provides a novel therapeutic avenue and an exciting future challenge that will be beneficial for patients with chronic inflammatory lung diseases, and potentially as an antiproliferative treatment for other neoplastic diseases like lung cancer and lymphangioleiomyomatosis.
